Your session is about to expire
← Back to Search
Pembrolizumab for Prostate Cancer
This trial is assessing whether the addition of pembrolizumab to docetaxel and prednisone improves outcomes in men with mCRPC who have not received prior chemotherapy for mCRPC.
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2021 Phase 3 trial • 453 Patients • NCT03066778
Awards & Highlights
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there any caps on recruitment for this experiment?
"Unfortunately, this particular study is not looking for any new participants at the moment. Although, it's important to note that the last update was on November 3rd, 2022. There are 1289 other trials searching for patients with prostate cancer and 2155 Pembrolizumab admitting patients right now."
How many sites are hosting this research project?
"There are 37 medical centres currently conducting this trial, with several notable locations being Durham, Toronto and Cleveland. If you're interested in participating, try to select a site close to minimize travel."
Can new participants still join this research initiative?
"The latest information from clinicaltrials.gov reports that this trial is not currently enrolling patients. This study was first posted on May 2nd, 2019 and updated November 3rd, 2020. There are other 3400+ trials currently looking for participants."
What are the chief medical benefits of Pembrolizumab?
"Pembrolizumab is a common treatment for eye conditions. It can also help patients with ulcerative colitis, varicella-zoster virus acute retinal necrosis, and other diseases."
What are the end goals that researchers hope to achieve with this trial?
"The primary aim of this oncology study, which will span a maximum of 36 months, is to observe and record the Overall Survival rate of participants. Additionally, researchers are looking at secondary objectives such as Time to Initiation of the First Subsequent Anti-cancer Therapy (TFST), Prostatei-cancer Therapy (TFST), Prostate-specific Antigen (PSA) Response Rate, and Duration of Response (DOR)."
What are the possible dangers of Pembrolizumab?
"Pembrolizumab has received a score of 3 for safety. This is due to the fact that it is in Phase 3 clinical trials, meaning there is significant data supporting both its efficacy and safety."
Share this study with friends